Department of Oncology, Beijing Friendship Hospital, Capital Medical University, #95 Yong An Road, Beijing, Xicheng District, China.
Yale School of Medicine, New Haven, CT, USA.
Mol Med. 2020 Apr 9;26(1):30. doi: 10.1186/s10020-020-00156-4.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with high mortality, which threats peoples' health. Unfortunately, the pathogenesis of PDAC remains unclear. Recent studies have indicated that long non-coding RNAs (lncRNAs) can regulate the development and progression of malignant tumors through varying mechanisms. LncRNA H19 has a unique expression profile and can act as a sponger of specific miRNAs to regulate the pathogenic process of many diseases, including PDAC and several other types of cancers. Here, we review the research approaches to understanding the regulatory role of H19 and potential mechanisms in the progression of PDAC and other types of cancers and diseases. These studies suggest that H19 may be a novel therapeutic target for PDAC and our findings may open new revenues for scientific researches and development of valuable therapies for these diseases in the future.
胰腺导管腺癌（PDAC）是一种具有高死亡率的侵袭性恶性肿瘤，严重威胁着人们的健康。不幸的是，PDAC 的发病机制仍不清楚。最近的研究表明，长链非编码 RNA（lncRNA）可以通过不同的机制调节恶性肿瘤的发生和发展。lncRNA H19 具有独特的表达谱，可作为特定 miRNAs 的海绵体，调节 PDAC 和其他几种类型的癌症等多种疾病的发病过程。在这里，我们回顾了研究 H19 及其在 PDAC 和其他类型的癌症和疾病进展中的潜在机制的调控作用的方法。这些研究表明，H19 可能是 PDAC 的一个新的治疗靶点，我们的发现可能为未来这些疾病的科学研究和有价值治疗方法的开发开辟新的途径。
Zotero 插件